Medtronic [WtwhTicker symbol="MDT"](NYSE: MDT)[/WtwhTicker] today announced the first patient enrolled in the PELE trial of its Onyx liquid embolic system (LES). PELE (Peripheral Onyx Liquid Embolic) evaluates the safety of Onyx LES for the … [Read More...] about Medtronic enrolls first patient in study for Onyx liquid embolic system
Main Content
Drug Tech
Today on Drug Delivery Business
- Medtronic enrolls first patient in study for Onyx liquid embolic system
- BD issues voluntary recall on certain Alaris infusion pump modules
- Sequel Med Tech expects full twiist launch in the fall
- Insulet hires new chief HR officer from J&J
- Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
- Medtronic Diabetes names CFO with consumer experience ahead of separation
- Diabeloop launches insulin delivery algorithm in Germany
Sponsored Content

Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Manufacturing automation is crucial to achieving the precision, quality, and volume required in the medical device industry. Advanced robotics, AI, modular designs, and wireless technology offer the … [Read More...] about Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Featured Posts

BD issues voluntary recall on certain Alaris infusion pump modules
By Sean Whooley
BD (NYSE:BDX) announced a voluntary recall related to certain Alaris and Alaris infusion pump modules. Affected Alaris products may have been serviced with previously recalled bezel kit assemblies. BD in 2019 recalled those kit assemblies … [Read More...] about BD issues voluntary recall on certain Alaris infusion pump modules

Sequel Med Tech expects full twiist launch in the fall
By Sean Whooley
Sequel Med Tech has offered insight into the next steps of the launch of its twiist automated insulin delivery (AID) system. The company shared at last month's American Diabetes Association’s 85th Scientific Sessions in Chicago that it planned to … [Read More...] about Sequel Med Tech expects full twiist launch in the fall

Insulet hires new chief HR officer from J&J
By Sean Whooley
Insulet (Nasdaq:PODD) announced that it named Lisa Blair Davis as its new SVP and chief human resources officer. She joins the automated insulin delivery technology maker from Johnson & Johnson. There, she most recently served as VP of global … [Read More...] about Insulet hires new chief HR officer from J&J

Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
By Sean Whooley
Breakthrough T1D (formerly JDRF) and Mattel announced a partnership to debut the first Barbie doll with type 1 diabetes (T1D). They say the global collaboration reflects a shared commitment to ensure that people with T1D are "seen, heard and … [Read More...] about Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Medtronic Diabetes names CFO with consumer experience ahead of separation
By Sean Whooley
Medtronic (NYSE:MDT) announced today that it appointed Chad Spooner as CFO of MiniMed in advance of its intended separation. Effective July 14, Spooner takes responsibility for overseeing the finance function for Medtronic Diabetes/MiniMed. His … [Read More...] about Medtronic Diabetes names CFO with consumer experience ahead of separation

Diabeloop launches insulin delivery algorithm in Germany
By Sean Whooley
Diabeloop today announced the commercial availability of its DBLG1 algorithm with the Dana-i insulin pump from Sooil in Germany. The companies distribute their automated insulin delivery offering through Mediq, a leading European diabetes … [Read More...] about Diabeloop launches insulin delivery algorithm in Germany

GlucoModicum has positive data for needle-free CGM
By Sean Whooley
GlucoModicum today announced positive outcomes from a clinical performance study of its needle-free continuous glucose monitor (CGM). Helsinki, Finland-based GlucoModicum said in a news release that the study helps put the company on "a clear path … [Read More...] about GlucoModicum has positive data for needle-free CGM

Lifecare takes next steps in CGM implant development
By Sean Whooley
Lifecare said on social media that it completed a significant milestone in the development of its continuous glucose monitor (CGM) implant. The Norway-based company says it completed the initial electromagnetic compatibility (EMC) testing of … [Read More...] about Lifecare takes next steps in CGM implant development

The biggest diabetes tech stories out of ADA 2025
By Sean Whooley
The biggest names in diabetes tech gathered in Chicago this past weekend for the American Diabetes Association's 85th Scientific Sessions. At last year's edition in Orlando, type 2 diabetes dominated the conversation. This time around, type 2 … [Read More...] about The biggest diabetes tech stories out of ADA 2025

Senseonics lays out hopes for next-gen CGM commercial timelines
By Sean Whooley
Senseonics (NYSE:SENS) has offered some insight into its plans for its next-generation implantable continuous glucose monitors (CGMs). The maker of the Eversense 365 year-long implantable CGM hosted an analyst event during the American Diabetes … [Read More...] about Senseonics lays out hopes for next-gen CGM commercial timelines
In case you missed it
- Mannkind looks to give those with diabetes another option through inhaled insulin
- Omnipod 5 rollout for type 2 advances as Insulet pursues next-gen automation
- Abbott Diabetes head talks Medtronic partnership, exciting times ahead
- PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
- Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy
- Next-gen Medtronic insulin pump reportedly set for FDA submission, patch pump on the way
- Analysts expect Beta Bionics patch pump launch by 2027
- A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
- Dexcom continues advances in AI for CGM, type 2 diabetes awareness
- Tandem continues to deliver more options, benefits for those with diabetes
- Breaking: Sequel to launch twiist automated insulin delivery system next month
- Dexcom shares U.S. report on CGM benefits for type 2 diabetes
- Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
- Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
- Abbott could pave new roads in diabetes management with dual sensor on the horizon
Clinical Trials

Medtronic enrolls first patient in study for Onyx liquid embolic system
Medtronic [WtwhTicker symbol=”MDT”](NYSE: MDT)[/WtwhTicker] today announced the first patient enrolled in the PELE trial of its Onyx liquid embolic system (LES). PELE (Peripheral Onyx Liquid Embolic) evaluates the safety of Onyx LES for the embolization of arterial hemorrhage in the peripheral vasculature. Dr. Christopher Stark performed the first procedure at Albany Medical Center. Onyx LES, […]

GlucoModicum has positive data for needle-free CGM
GlucoModicum today announced positive outcomes from a clinical performance study of its needle-free continuous glucose monitor (CGM). Helsinki, Finland-based GlucoModicum said in a news release that the study helps put the company on “a clear path to commercialization.” The study involved 646 participant visits, including individuals with type 2 diabetes and healthy volunteers. The company […]

Glucotrack first-in-human study of long-term CBGM implant meets endpoints
Glucotrack (Nasdaq:GCTK) today announced the results from the first-in-human clinical study of its long-term continuous blood glucose monitor (CBGM). Rutherford, New Jersey-based Glucotrack shared findings at the American Diabetes Association’s 85th Scientific Sessions in Chicago. (See all the biggest stories out of ADA 2025 here.) Glucotrack’s device features no on-body external component. The company designed […]

The biggest diabetes tech stories out of ADA 2025
The biggest names in diabetes tech gathered in Chicago this past weekend for the American Diabetes Association’s 85th Scientific Sessions. At last year’s edition in Orlando, type 2 diabetes dominated the conversation. This time around, type 2 remained a hot topic, alongside new players in the continuous glucose monitor (CGM) and automated insulin delivery market, […]

Mannkind looks to give those with diabetes another option through inhaled insulin
For those living with diabetes, MannKind offers a very different alternative to the current methods of insulin delivery. Founded in 1991 by Alfred E. Mann, a medtech visionary who played a large part in the wider adoption of insulin pumps as the founder of MiniMed, the company develops Afrezza — a fast-acting insulin formulation delivered […]